- Home
- MPV vs IPHA Comparison
MPV vs IPHA Comparison
Compare MPV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPV | IPHA |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.1M | 160.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPV | IPHA |
|---|---|---|
| Price | $18.77 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 10.4K | ★ 12.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.22 | $1.40 |
| 52 Week High | $21.00 | $2.63 |
Technical Indicators
Market Signals| Indicator | MPV | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 31.04 |
| Support Level | $18.64 | N/A |
| Resistance Level | $19.54 | $1.88 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 49.12 | 2.53 |
Price Performance
Historical ComparisonAbout MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.